Home » Stocks » NEXI

NexImmune, Inc. (NEXI)

Stock Price: $17.21 USD -0.62 (-3.48%)
Updated Jun 11, 2021 4:00 PM EDT - Market closed
Market Cap 388.59M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 12.63M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 11
Last Price $17.21
Previous Close $17.83
Change ($) -0.62
Change (%) -3.48%
Day's Open 17.75
Day's Range 17.18 - 17.80
Day's Volume 24,790
52-Week Range 17.06 - 28.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

GAITHERSBURG, Md., May 27, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted...

2 weeks ago - GlobeNewsWire

GAITHERSBURG, Md., May 19, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted...

3 weeks ago - GlobeNewsWire

GAITHERSBURG, Md., May 17, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted...

3 weeks ago - GlobeNewsWire

GAITHERSBURG, Md., April 21, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a target...

1 month ago - GlobeNewsWire

GAITHERSBURG, Md., March 31, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a target...

2 months ago - GlobeNewsWire

Last year was a monster year for the initial public offering market, and 2021 looks like it could provide a repeat performance.

Other stocks mentioned: BOLT, MASS, MDWT, OCDX
3 months ago - 24/7 Wall Street

GAITHERSBURG, Md., March 02, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a target...

3 months ago - GlobeNewsWire

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Biotech stocks and secondary and initial public offerings were well represented this week.

Other stocks mentioned: BMBL, FISV, ATEX, CRVS, DBTX, MTEM, ONCR ...
3 months ago - Benzinga

GAITHERSBURG, Md., Feb. 17, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body's own...

3 months ago - GlobeNewsWire

NexImmune, Inc., a clinical-stage biotechnology company developing a novel approach to immunotherapy...

4 months ago - GlobeNewswire

NexImmune, a Phase 1/2 biotech developing T cell immunotherapies for cancer, filed on Tuesday with the SEC to raise up to $86 million in an initial public offering.

4 months ago - NASDAQ

NexImmune, Inc. has filed to go public with an IPO on the NASDAQ.

4 months ago - SEC

About NEXI

NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent and durable immune response that mimics natural biology. Our mission is to create therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. Currently, we have two product candidates in human trials: NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM. It is important to note that we are earl... [Read more...]

Industry
Biotechnology
IPO Date
Feb 12, 2021
CEO
Scott Carmer
Employees
44
Stock Exchange
NASDAQ
Ticker Symbol
NEXI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for NexImmune is 33.33, which is an increase of 93.67% from the latest price.

Price Target
$33.33
(93.67% upside)